ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
Health secretary Jeremy Hunt to launch inquiry
Filings for drugs in blood cancer and breast cancer
Mundipharma’s third biosimilar tie-up with Celltrion
NICE says no to Halaven in second line breast cancer